20 articles
Daily anthocyanin supplementation helped over half of prediabetic participants return to normal glucose tolerance in just 12 weeks.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
New research links NAD+ imbalance to RYR1-related muscle disorders, potentially revealing cellular aging pathways.
Sodium propionate reduced liver inflammation and fat accumulation in diabetic mice fed high-fat, AGE-rich diets through multiple protective mechanisms.
Novel GLP-1 analogue NNC5840 achieves greater weight reduction than semaglutide by optimizing receptor signaling bias rather than potency.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
Scientists identify an NADH-dependent molecular switch linking glycolysis to mitochondrial ATP synthesis, revealing a new metabolic control point.
New research identifies choline kinase alpha as a key driver of diabetic retinopathy and microvascular dysfunction.
Combined mitochondrial therapy restored muscle function and reduced fatigue in mouse model of Gulf War Illness.
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
New research shows dietary methionine enhances kidney function to clear harmful inflammatory molecules from the bloodstream.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.
A 60-week RCT finds semaglutide 2.4 mg sustains ~240 kcal/day reduction even after appetite benefits diminish.
Combining cold exposure with exercise activates a key metabolic pathway to reduce liver fat and fibrosis more effectively than either intervention alone.
New research shows phosphatidylserine supplementation reduces liver fat and inflammation while improving glucose control through enhanced fat metabolism.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
Simple sugar supplement dramatically improved diabetes symptoms in mice by stopping inflammatory cells from releasing disease-causing particles.
NIH study identifies metabolic mechanism behind controversial skin condition and demonstrates successful treatment with mitochondrial complex I inhibitors.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
